GlassScriptPhysician profile
Nicholas Winn
NPI 1790295095
$2,179.98
in general payments reported to CMS, 2019-2025
20 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $190 · 2023: $414 · 2024: $706 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.07 |
| Education | $398.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $379.34 | 2021-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $377.01 | 2022-2025 | |
| Janssen Biotech, INC. | $264.60 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $214.31 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $183.46 | 2023-2024 | Vtama |
| Abbvie INC. | $160.95 | 2021-2025 | |
| Leo Pharma INC. | $103.08 | 2021-2025 | Adbry |
| Incyte Corporation | $82.33 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $81.51 | 2021-2024 | Ebglyss, Olumiant, Taltz |
| Biofrontera INC. | $74.60 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $55.35 | 2022-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $53.87 | 2021-2025 | Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $34.47 | 2024-2025 | Zoryve |
| Organon LLC | $20.20 | 2025 | Vtama |
| Amgen INC. | $19.24 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $18.75 | 2023 | Tremfya |
| Smith+Nephew, INC. | $15.63 | 2021 | |
| Genzyme Corporation | $14.98 | 2025 | |
| Ucb, INC. | $14.21 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Winn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.